A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant MÃ¼llerian Cancer
This is a prospective, open label, dose escalating, Phase I/II study, measuring mainly the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel in patients with platinum resistant ovarian cancer.
Platinum Resistant Ovarian Cancer
DRUG: Paclitaxel
Define toxicities, Define toxicities of a limited number of doses of combination VB-111 and weekly paclitaxel spanning anticipated effective doses., 2 years
This is a prospective, open label, dose escalating, Phase I/II study, measuring mainly the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel in patients with platinum resistant ovarian cancer.